SEASTAR MEDICAL HOLDING CORPORATION reports a Return on Equity (ROE) of -162.67%.

What is ICU's dividend yield?

SEASTAR MEDICAL HOLDING CORPORATION offers a dividend yield of 0.00%.

What is ICU's Quality Score?

Our AI rates ICU's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ICU?

Our AI Timing Score for ICU is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ICU belong to?

SEASTAR MEDICAL HOLDING CORPORATION is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

ICU (NASDAQ) Stock Analysis | SEASTAR MEDICAL HOLDING CORPORATION

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ICU AI Analysis Summary

Our AI summary for ICU: SEASTAR MEDICAL HOLDING CORPORATION (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -162.67%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ICU

SEASTAR MEDICAL HOLDING CORPORATION

US:NASDAQ STOCK Healthcare >> Biotechnology News 67

USD 3.13

-0.05 (-1.57%) Day Change

Watchlist Portfolio Compare Chart

0.05

D/E

-162.7%

ROE

-105.7%

ROA

0.00%

Div Yield

SEASTAR MEDICAL HOLDING CORPORATION
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.13 Price -0.05 (-1.57%) Day Change	NEWS SCORE: 67

ICU, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	67
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.13
PBV / Sector	1.74 / 5.20
Earning Per Share	-2.93

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.31 M GREAT
Average 1W Daily Value	0.20 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-828.62 / 98.71
NPM Average (%) / Sector	-6,735.27 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-105.65 / 27.02
ROA Average (%) / Sector	-445.75 / -368.17
ROA Change Average (%) / Sector	-22.71 / 5,404.12
ROE (%) / Sector	-162.67 / 3.47
ROE Average (%) / Sector	231.62 / 6.51 GREAT
ROE Change Average (%) / Sector	125.31 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:59
Symbol	ICU
Name	SEASTAR MEDICAL HOLDING CORPORATION
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	4.00 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	12.71 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3513 Brighton Boulevard, Denver, CO, United States, 80216

Phone: 844 427 8100

Website: https://seastarmedical.com

Sector: Healthcare >> Biotechnology

Description: SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.